PDF herunterladen
Thromb Haemost 1991; 65(03): 296-299
DOI: 10.1055/s-0038-1648138
Original Article
Schattauer GmbH Stuttgart

In Vivo Antiaggregatory Action of Platelet-Activating Factor in Beagle Dogs: Role for Prostacyclin

Ferenc Hermán
The Department of Pharmacodynamics and Pathophysiology, Semmelweis University Medical School, Budapest, Hungary
,
Kálmán Magyar
The Department of Pharmacodynamics and Pathophysiology, Semmelweis University Medical School, Budapest, Hungary
,
János G Filep
The Department of Pharmacodynamics and Pathophysiology, Semmelweis University Medical School, Budapest, Hungary
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received: 26. Juni 1990

Accepted after revision 26. Oktober 1990

Publikationsdatum:
02. Juli 2018 (online)

  als PDF herunterladen  Lizenzen und Reprints

Summary

The effects of platelet-activating factor (PAF) on in vivo platelet aggregation were studied in anaesthetized beagle dogs by using the extracorporeal filter-loop technique. Intraarterial administration of PAF caused an immediate increase in filter pressure, indicating enhanced in vivo platelet aggregation. Intravenous administration of PAF (3-100 ng kg−1) resulted in a transient dose-dependent inhibition of spontaneous platelet aggregation on the filter with concomitant elevation in plasma 6-keto-PGF1Α levels. These changes were significantly attenuated by pretreatment of the animals either with BN 52021 (4 mg kg−1), a specific PAF receptor antagonist or with acetylsalicylic acid (25 mg kg−1). Intraarterial infusion of exogenous prostacyclin at concentrations similar to those observed following intravenous PAF administration, resulted in a transient inhibition of the spontaneous platelet aggregation. These data provide evidence for prostacyclin release in response to PAF, and suggest that prostacyclin may mediate the in vivo anti-aggregatory action of PAF in anaesthetized dogs.

 

  • REFERENCES

  • 1 Braquet P, Touqui L, Shen TY, Vargaftig BB. Perspectives in platelet-activating factor research. Pharmacol Rev 1987; 39: 197-145
    PubMedGoogle Scholar
  • 2 Janero DR, Burghardt B, Burghardt C. Specific binding of 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor) to the intact canine platelet. Thromb Res 1988; 50: 789-802
    CrossrefPubMedGoogle Scholar
  • 3 Apprill P, Schmitz JM, Campbell WB, Tilton G, Ashton J, Raheja S, Buja LM, Willerson JT. Cyclic blood flow variations induced by platelet-activating factor in stenosed canine coronary arteries despite inhibition of thromboxane synthetase, serotonin receptors, and a-adrenergic receptors. Circulation 1985; 72: 397-405
    CrossrefPubMedGoogle Scholar
  • 4 Moncada S, Vane JR. Arachidonic acid metabolites and the interactions between platelets and blood vessel walls. N Engl J Med 1979; 300: 1142-1147
    CrossrefPubMedGoogle Scholar
  • 5 Needleman P, Wyche A, Raz A. Platelet and blood vessel arachido-nate metabolism and interactions. J Clin Invest 1979; 63: 345-349
    CrossrefPubMedGoogle Scholar
  • 6 Vanhoutte PM, Houston DS. Platelets, endothelium, and vasospasm. Circulation 1985; 72: 728-734
    CrossrefPubMedGoogle Scholar
  • 7 Chiercia S, Patrono C. Role of platelet and vascular eicosanoids in the pathophysiology of ischemic heart disease. Fed Proc 1987; 46: 81-88
    PubMedGoogle Scholar
  • 8 Hermán F, Hadházy P, Magyar K. In vivo measurement of the disaggregatory action of prostacyclin. A methodological study. Thromb Res 1986 44. 575-585
    PubMedGoogle Scholar
  • 9 Homstra G. Method to determine the degree of ADP-induced platelet aggregation in circulating blood (Filter-loop technique). Br J Haematol 1970; 19: 321-329
    CrossrefPubMedGoogle Scholar
  • 10 Broersma RJ, Dickerson GD, Sullivan MS. The determination of platelet aggregation by filtration pressure in circulating dog blood. Thromb Diath Heaemorrh 1973; 29: 201-210
    PubMedGoogle Scholar
  • 11 Braquet P, Spinnewyn B, Braquet M, Bourgain RM, Taylor JF, Etienne A, Drieu K. BN 52021 and related compounds: a new series of highly specific PAF-acether receptor antagonists isolated from Ginkgo biloba. Blood Vessels 1985; 6: 559-572
    PubMedGoogle Scholar
  • 12 Földes-Filep E, Braquet P, Filep J. Inhibition by BN 52021 (Gink-golide B) of the binding of [3H]-platelet-activating factor to human neutrophil granulocytes. Biochem Biophys Res Commun 1987; 148: 1412-1417
    CrossrefPubMedGoogle Scholar
  • 13 Nunez D, Chignard M, Korth R, Le Couedic JP, Norel X, Spinnewyn B, Braquet P, Benveniste J. Specific inhibition of PAF-acether-induced platelet activation by BN 52021 and comparison with the PAF-acether inhibitors, kadsurenone and CV 3988. Eur J Pharmacol 1986; 123: 197-205
    CrossrefPubMedGoogle Scholar
  • 14 Filep J, Hermán F, Braquet P, Mózes T. Increased levels of platelet-activating factor in blood following intestinal ischemia. Biochem Biophys Res Commun 1989; 158: 353-359
    CrossrefPubMedGoogle Scholar
  • 15 Flower RJ, Gryglewski R, Herbaczynska-Cedro K, Vane JR. The effects of antiinflammatory drugs on prostacyclin biosynthesis. Nature 1972; 238: 104-106
    PubMedGoogle Scholar
  • 16 Hermán F, Magyar K, Chabrier PE, Braquet P, Filep J. Prostacyclin mediates antiaggregatory and hypotensive actions of endothelin in anaesthetized beagle dogs. Br J Pharmacol 1989; 98: 38-40
    CrossrefPubMedGoogle Scholar
  • 17 Wilcoxon F, Wilcox RA. Some Rapid Approximate Statistical Procedures. Lederle Laboratories, Pearl-River, NY 1964; 36-38
    PubMedGoogle Scholar
  • 18 Chignard M, Le Couedic JP, Tence M, Vargaftig BB, Benveniste J. The role of platelet-activating factor in platelet aggregation. Nature 1979; 279: 799-800
    CrossrefPubMedGoogle Scholar
  • 19 McManus LM, Hanahan DJ, Pinckard RN. Human platelet stimulation by acetyl-glyceryl ether phosphorylcholine. J Clin Invest 1981; 67: 903-906
    CrossrefPubMedGoogle Scholar
  • 20 Chesney CM, Pifer DD, Byers LW, Muirhead EE. Effect of platelet-activating factor (PAF) in human platelets. Blood 1982; 59: 582-5
    PubMedGoogle Scholar
  • 21 Benveniste J, Chignard M. A role for PAF-acether (platelet-activating factor) in platelet-dependent vascular diseases. Circulation 1985; 72: 713-717
    CrossrefPubMedGoogle Scholar
  • 22 Küster LJ, Filep J, Frölich JC. Mechanism of PAF-induced platelet aggregation in man. Thromb Res 1986; 43: 425-433
    CrossrefPubMedGoogle Scholar
  • 23 D’Humieres S, Russo-Marie F, Vargaftig BB. PAF-acether-induced synthesis of prostacyclin by human endothelial cells. Eur J Pharmacol 1986; 131: 13-19
    CrossrefPubMedGoogle Scholar
  • 24 Mehta J, Wargovich T, Nichols WW. Biphasic effects of platelet-activating factor on coronary blood flow in anesthetized dogs. Prostaglandins Leukotrienes Med 1986; 21: 87-95
    CrossrefPubMedGoogle Scholar
  • 25 Bussolino F, Camussi G, Aglietta M, Braquet P, Bosia A, Pescarmona G, Sanavio F, D’Urso N, Marchisio PC. Human endothelial cells are target for platelet-activating factor. J Immunol 1987; 139: 2439-0046
    PubMedGoogle Scholar
  • 26 Weksler BB, Ley ChW, Jaffe EA. Stimulation of endothelial cell prostacyclin production by thrombin, trypsin, and the ionophore A 23187. J Clin Invest 1978; 62: 923-030
    CrossrefPubMedGoogle Scholar
  • 27 Hemker DJ, Shebuski RJ, Aiken JW. Release of a prostacyclin-like substance into the circulation of dogs by intravenous adenosine 5-diphosphate. J Pharmacol Exp Ther 1980; 212: 246-252
    PubMedGoogle Scholar
  • 28 Hermán F, Hadházy P, Magyar K. Quantitative determination of endogenous PGI2 release in anaesthetized beagle dogs. Thromb Haemostas 1987; 58: 109
    PubMedGoogle Scholar
  • 29 Mùzes T, Wieszt E. Intestinal and arterial plasma thromboxane and prostacyclin levels in shock: Effects of indomethacin. J Surg Res 1989; 47: 482-506
    CrossrefPubMedGoogle Scholar